Back to first-pass browser

First-pass extracted concept

engineered iPSC-derived natural killer cells

Candidate: concept label1 source documents5 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

iNK cells, iPSC-derived NK cells

Extracted Explainers

What the tool is doing

This concept refers to NK cells generated from induced pluripotent stem cells and further improved by genetic modification for anti-cancer immunotherapy. The review frames them as an off-the-shelf-like, controllable source of NK cells.

Source 1DOIPubMed

Resources required

The abstract supports the need for iPSCs, defined culture systems for NK generation, and genetic modification capability. It does not provide protocol-level manufacturing details.

Source 1DOIPubMed

What problem it solves

It addresses the scalability, consistency, and variability problems associated with sourcing NK cells from peripheral blood. It also provides a common source of genetically modifiable NK cells for therapy development.

Source 1DOIPubMed

What it does not solve

The abstract does not show that engineered iPSC-NK cells solve all translational or clinical efficacy challenges. Specific safety, manufacturing, and comparative performance limits are not detailed in the provided evidence.

Source 1DOIPubMed

Alternatives

The abstract explicitly contrasts this platform with peripheral-blood-derived NK cell sourcing. It also situates NK cells within allogeneic adoptive cell immunotherapies more broadly.

Source 1DOIPubMed

Evidence Snippets

Induced pluripotent stem cells (iPSCs) are emerging as a platform to create specific cells with highly controlled processes, allowing for a common cell source for cell therapies and offering a promising inexhaustible source of genetically modifiable NK cells.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1performance summarysupports2025Source 1DOIPubMed

Genetic modification of iPSCs has achieved improvements in cancer targeting, expansion, persistence, and cytotoxic functionality of iPSC-derived NK cells in vitro and in vivo.

Quoted textsource-backed
Finally, we summarise the improvements in cancer targeting, expansion, persistence and cytotoxic functionality of iPSC-derived NK (iNK) cells both in vitro and in vivo, achieved through genetic modification of iPSCs, as well as recent related clinical trials.
Claim 2platform advantagesupports2025Source 1DOIPubMed

iPSCs are emerging as a controlled and promising inexhaustible source of genetically modifiable NK cells for cell therapies.

Quoted textsource-backed
Induced pluripotent stem cells (iPSCs) are emerging as a platform to create specific cells with highly controlled processes, allowing for a common cell source for cell therapies and offering a promising inexhaustible source of genetically modifiable NK cells.
Claim 3problem statementsupports2025Source 1DOIPubMed

Peripheral-blood sourcing of NK cells poses scalability, consistency, and variability challenges.

Quoted textsource-backed
However, sourcing NK cells from peripheral blood poses challenges in terms of scalability, consistency and variability.
Claim 4rationalesupports2025Source 1DOIPubMed

NK cells are potent tumoricidal agents that can be used for cancer immunotherapy.

Quoted textsource-backed
Natural killer (NK) cells are increasingly recognised as potent tumoricidal agents that can be utilised for cancer immunotherapy.
Claim 5review scopesupports2025Source 1DOIPubMed

Recent developments include generating iPSC-derived NK cells in defined culture systems and genetically modifying them to improve iPSC-NK cell therapy.

Quoted textsource-backed
This review highlights recent developments in the field of generating iPSC-derived NK cells in defined culture systems, and advancements in genetic modification to improve iPSC-NK cell therapy.